Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 13;13(2):277.
doi: 10.3390/cancers13020277.

The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack

Tamiem Adam  1   2   3 , Therese M Becker  1   4 , Wei Chua  1   2   3 , Victoria Bray  3 , Tara L Roberts  1   2   4
Affiliations
Review

The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack

Tamiem Adam et al. Cancers (Basel). .

Abstract

Immune checkpoint inhibitors (ICIs) are being increasingly utilised in a variety of advanced malignancies. Despite promising outcomes in certain patients, the majority will not derive benefit and are at risk of potentially serious immune-related adverse events (irAEs). The development of predictive biomarkers is therefore critical to personalise treatments and improve outcomes. A number of biomarkers have shown promising results, including from tumour (programmed cell death ligand 1 (PD-L1), tumour mutational burden (TMB), stimulator of interferon genes (STING) and apoptosis-associated speck-like protein containing a CARD (ASC)), from blood (peripheral blood mononuclear cells (PBMCs), circulating tumour DNA (ctDNA), exosomes, cytokines and metal chelators) and finally the microbiome.

Keywords: NSCLC; biomarker; immunotherapy; melanoma; predictive; renal cancer; urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reck M., Rodriguez-Abreu D., Robinson A.G., Hiu R., Csoszi T., Fulop A., Gottfried M., Peled N., Tafreshi A., Cuffe S., et al. Pembrolizumab versus chemotherapy of PD-L1 positive NSCLC. NEJM. 2016;375:1823. doi: 10.1056/NEJMoa1606774. - DOI - PubMed
    1. Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilotet D., Thomas C.A., Barelsi F., et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. NEJM. 2018;378:2288. - PubMed
    1. Bellmunt J., de Wit R., Vaughn D.J., Fardet Y., Lee J.-L., Fong L., Vogelzang N.J., Climent M.A., Petrylak D.P., Chouieri T.K., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. NEJM. 2017;376:1015. doi: 10.1056/NEJMoa1613683. - DOI - PMC - PubMed
    1. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., Tykodi S.S., Sosman J.A., Procopio G., Plimack E.R., et al. Nivolumab versus everolimus in advanced renal cell carcinoma. NEJM. 2015;373:1803. - PMC - PubMed
    1. Subbiah V., Solit D.B., Kurzrock R. The FDA approval of pembrolizumab for adult and pediatric patients with tumour mutational burden (TMB) ≥ 10: A decision centered on empowering patients and their physicians. Ann. Oncol. 2020;31:1115–1118. doi: 10.1016/j.annonc.2020.07.002. - DOI - PubMed

LinkOut - more resources